Abstract
Hyperglycemia in pregnancy (HIP) is the umbrella term for conditions including gestational diabetes mellitus, type 1(T1DM), and type 2 diabetes (T2DM) in pregnancy. HIP is considered a high risk for both the mother and the fetus. Intrauterine exposure to HIP is associated with metabolic disease in the offspring. These risks can be minimized with good control of diabetes before and during pregnancy. Universal screening (testing all pregnant women) is more relevant to the Asian population including Pakistani women at high risk. According to the IADPSG criteria, a 75-g OGTT should be offered to all pregnant women between 24 and 28weeks of gestation not previously identified with diabetes. Management strategies include medical nutrition therapy and pharmacological agents including insulin and/or metformin. Postpartum screening is recommended 4 to 12weeks after delivery with a 75-g OGTT. Effective intervention requires universal antenatal screening for GDM, optimal treatment and adherence, and rigorous postpartum follow-up and preventive care.
Original language | English |
---|---|
Title of host publication | BIDE's Diabetes Desk Book: For Healthcare Professionals |
Editors | Abdul Basit, Muhammad Y. Ahmedani |
Place of Publication | U.K. |
Publisher | Elsevier |
Pages | 317-335 |
Number of pages | 19 |
ISBN (Electronic) | 9780443221071 |
ISBN (Print) | 9780443221064 |
DOIs | |
Publication status | Published - 1 Jan 2023 |